590 related articles for article (PubMed ID: 31303196)
1. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS).
Evoy KE; Covvey JR; Peckham AM; Ochs L; Hultgren KE
Res Social Adm Pharm; 2019 Aug; 15(8):953-958. PubMed ID: 31303196
[TBL] [Abstract][Full Text] [Related]
2. Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system.
Vickers-Smith R; Sun J; Charnigo RJ; Lofwall MR; Walsh SL; Havens JR
Drug Alcohol Depend; 2020 Jan; 206():107709. PubMed ID: 31732295
[TBL] [Abstract][Full Text] [Related]
3. Abuse and Misuse of Pregabalin and Gabapentin.
Evoy KE; Morrison MD; Saklad SR
Drugs; 2017 Mar; 77(4):403-426. PubMed ID: 28144823
[TBL] [Abstract][Full Text] [Related]
4. An analysis of suicidal and self-injurious behavior reports with antiseizure medications in the FDA adverse event database.
Porwal MH; Razzak AN; Kumar V; Obeidat AZ; Sharma U
Epilepsy Res; 2024 Jul; 203():107382. PubMed ID: 38761467
[TBL] [Abstract][Full Text] [Related]
5. Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update.
Evoy KE; Sadrameli S; Contreras J; Covvey JR; Peckham AM; Morrison MD
Drugs; 2021 Jan; 81(1):125-156. PubMed ID: 33215352
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases.
Mukai R; Hasegawa S; Umetsu R; Nakao S; Shimada K; Uranishi H; Masuta M; Suzuki H; Nishibata Y; Nakamura M
J Clin Pharm Ther; 2019 Apr; 44(2):285-291. PubMed ID: 30569470
[TBL] [Abstract][Full Text] [Related]
7. Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France.
Driot D; Jouanjus E; Oustric S; Dupouy J; Lapeyre-Mestre M
Br J Clin Pharmacol; 2019 Jun; 85(6):1260-1269. PubMed ID: 30737829
[TBL] [Abstract][Full Text] [Related]
8. A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.
Chiappini S; Schifano F
CNS Drugs; 2016 Jul; 30(7):647-54. PubMed ID: 27312320
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the Safety Signal for the Abuse Potential of Pregabalin and Gabapentin Using the FAERS Database and Big Data Search Analytics.
Papazisis G; Spachos D; Siafis S; Pandria N; Deligianni E; Tsakiridis I; Goulas A
Front Psychiatry; 2021; 12():640264. PubMed ID: 34093263
[No Abstract] [Full Text] [Related]
10. Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability.
Evoy KE; Peckham AM; Covvey JR; Tidgewell KJ
J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S89-S99. PubMed ID: 34396549
[TBL] [Abstract][Full Text] [Related]
11. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
12. [On the risk of dependence on gabapentinoids].
Bonnet U; Scherbaum N
Fortschr Neurol Psychiatr; 2018 Feb; 86(2):82-105. PubMed ID: 29179227
[TBL] [Abstract][Full Text] [Related]
13. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
Zhou Z; Hultgren KE
JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
[TBL] [Abstract][Full Text] [Related]
14. How addictive are gabapentin and pregabalin? A systematic review.
Bonnet U; Scherbaum N
Eur Neuropsychopharmacol; 2017 Dec; 27(12):1185-1215. PubMed ID: 28988943
[TBL] [Abstract][Full Text] [Related]
15. Respiratory concerns of gabapentin and pregabalin: What does it mean to the pharmacovigilance systems in developing countries?
Shrestha S; Palaian S
F1000Res; 2020; 9():32. PubMed ID: 33728039
[TBL] [Abstract][Full Text] [Related]
16. Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland.
Torrance N; Veluchamy A; Zhou Y; Fletcher EH; Moir E; Hebert HL; Donnan PT; Watson J; Colvin LA; Smith BH
Br J Anaesth; 2020 Aug; 125(2):159-167. PubMed ID: 32571568
[TBL] [Abstract][Full Text] [Related]
17. Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database.
Bossard JB; Ponté C; Dupouy J; Lapeyre-Mestre M; Jouanjus E
Clin Drug Investig; 2016 Sep; 36(9):735-742. PubMed ID: 27300651
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients.
Ibiloye EA; Barner JC; Lawson KA; Rascati KL; Evoy KE; Peckham AM
Clin Drug Investig; 2021 Mar; 41(3):245-253. PubMed ID: 33580482
[TBL] [Abstract][Full Text] [Related]
19. Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases.
Petrović NZ; Pejčić AV; Milovanović IR
Expert Opin Drug Saf; 2024 Jan; 23(1):67-78. PubMed ID: 38062555
[TBL] [Abstract][Full Text] [Related]
20. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).
Kwan ATH; Rosenblat JD; Mansur RB; Teopiz KM; McIntyre RS
J Affect Disord; 2024 Sep; 360():421-426. PubMed ID: 38795777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
